AAU News 1.45 07/15/2014 04:22:49 Almaden Minerals (AAU)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Almaden Minerals (AAU) 1.45 $AAU

Almaden Completes Infill Drilling Program, Hits 62.00 Meters of 0.96 g/t Au, 76.4 g/t Ag (2.5 g/t AuEq) at Ixtaca, Mexico
Marketwire - Wed Jul 09, 8:04AM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM)(NYSE MKT: AAU) is pleased to announce the results from Almaden's ongoing 2014 Ixtaca Zone drill program at the Company's 100% owned Tuligtic project, Mexico. Recently the company released a positive PEA on the Ixtaca deposit (see news release dated April 16th, 2014). The mineral resources incorporated into the PEA mine plan were comprised of 29% Measured, 55% Indicated and 16% Inferred. The results reported today are from drilling carried out subsequent to the 2014 resource update and PEA and designed to upgrade resources remaining in the inferred category to the higher confidence measured and indicated categories. Infill drilling is now complete and the Company's 2014 drilling is currently focussed on exploring the large and highly prospective Tuligtic concession for gold-silver deposits. Highlights from the holes released today include the following intercepts (a more complete list of intercepts is shown in the table below):

Almaden re-appoints eight board directors at its AGM
M2 - Mon Jul 07, 3:31AM CDT
Mineral company Almaden Minerals (TSX:AMM.TO)(NYSE MKT:AAU) announced on Friday the re-election of eight directors at its Annual General Meeting held on 26 June 2014.

Almaden Announces Re-Election of Directors
Marketwire - Thu Jul 03, 6:27PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM)(NYSE MKT: AAU) is pleased to announce the re-election of its directors at the Company's June 26, 2014 Annual General Meeting.

AndeanGold - Urumalqui Ag - Au Project, Peru, 40% Option Agreement Update
Marketwire - Wed Jun 18, 1:33AM CDT
AndeanGold Ltd. ("the Company" or "AndeanGold" (TSX VENTURE: AAU)(LMA: AAU) is pleased to announce that Gitennes Exploration Inc. ("Gitennes" and the Company have signed a further amendment to the Share Sale and Mining Agreement dated May 17, 2012, as previously amended on May 10, 2013, September 16, 2013 and February 27, 2014 (collectively, the "Agreement", which revises the timing of future payment obligations stipulated in the Agreement. The Agreement provides the Company with the right to acquire Gitennes' 40% interest in the Urumalqui Ag-Au Project in Peru (see news releases of May 22, 2012, May 21, 2013, September 19, 2013 and February 28, 2014).

Almaden Files Preliminary Economic Assessment Technical Report for Its Ixtaca Gold-Silver Deposit, Mexico
Marketwire - Fri May 30, 11:41AM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM)(NYSE MKT: AAU) announces that the independent NI 43-101 Preliminary Economic Assessment Technical Report (the "PEA", for its gold-silver Ixtaca Deposit, Mexico, has been completed and filed on SEDAR. A summary of findings from the PEA were announced in Almaden's press release issued April 16th, 2014. The full report, "Preliminary Economic Assessment of the Ixtaca Project", prepared by Moose Mountain Technical Services ("MMTS" can be obtained from www.sedar.com. The independent qualified persons responsible for preparing the Ixtaca Preliminary Economic Assessment are Jesse Aarsen, P.Eng. and Tracey Meintjes, P.Eng. of MMTS, Ken Embree, P.Eng. of Knight Piesold Ltd. ("KP", Kris Raffle, P.Geo. of APEX Geoscience Ltd., and Gary Giroux, M.A.Sc., P.Eng. of Giroux Consultants Ltd., all of whom act as independent consultants to the Company, are Qualified Persons as defined by National Instrument 43-101 ("NI 43-101" and have reviewed and approved the contents of this news release.

AndeanGold Announces Board of Directors Appointment
Marketwire - Tue May 27, 11:21AM CDT
AndeanGold Ltd. ("the Company" or "AndeanGold" (TSX VENTURE: AAU)(LMA: AAU) is pleased to announce that Mr. Sergio Stiglich has been appointed to AndeanGold's board of directors. Mr. Stiglich, who is based in Lima, Peru, has over 20 years of experience in the Financial Industry. He is Chief Executive Officer of Numa Americas Corp (USA), a subsidiary of Numa Asset Management ("Numa", and also serves as the lead portfolio manager of the Numa Defender Fixed Income Fund. He joined Numa in 2012 after almost 14 years with Bank of America Merrill Lynch. Prior thereto, he was affiliated with Banco de Credito del Peru. Mr. Stiglich holds 2 Bachelors of Arts and a Master of Arts in Financial Management from the Catholic University of America. He has also completed a Post Graduate Degree on Capital Markets from the Pontificia Universidad Catolica del Peru. Numa is a diversified financial services firm providing the capital markets with innovative strategies through quantitative and qualitative research, portfolio and risk management expertise, wealth management, investment advisory, financial structuring, hedging strategies and complex use of derivatives.

Almaden Reports on Confidentiality Agreements
Marketwire - Fri May 09, 6:11PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM)(NYSE MKT: AAU), in response to third party enquiries, reports that it has entered into a number of confidentiality agreements in respect of its various projects.

Almaden Provides Exploration Update for the Ixtaca Gold-Silver Zone of the Tuligtic Project, Mexico
Marketwire - Tue Apr 01, 8:04AM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM)(NYSE MKT: AAU) is pleased to report on the on-going exploration activities at the Company's 100% owned Tuligtic project and Ixtaca Zone. A Preliminary Economic Assessment ("PEA" is currently being prepared by the independent engineering consultant groups Knight Piesold Ltd. and Moose Mountain Technical Services. On the project, the Company has commenced drilling operations. Currently one drill is working on a geo-mechanical data gathering program required for potential future studies. Geotechnical holes are also planned as part of this engineering focussed drill program. A second drill has been working on a small infill drilling program which is about to finish. For the remainder of 2014, Almaden plans to focus drilling on high-priority gold-silver exploration targets located near the Ixtaca deposit. These targets, defined by epithermal alteration, surface anomalous geochemistry and geophysics, are considered by the Company to represent unique opportunities for discovery adjacent to the Ixtaca deposit, a blind drilling discovery made by Almaden in 2010. Other work currently underway includes environmental baseline studies and more advanced metallurgical test work.

Almaden Files Form 20-F Documentation
Marketwire - Mon Mar 31, 5:43PM CDT
Almaden Minerals Ltd. ("Almaden" or "the Company" (TSX: AMM)(NYSE MKT: AAU) announces that its Form 20-F for the fiscal year ended December 31, 2013 has been filed with the U.S. Securities and Exchange Commission. The Form 20-F and the Company's audited consolidated financial statements for the years ended December 31, 2013 and 2012, are available on the Company's website at www.almadenminerals.com.

AndeanGold Announces Settlement Of Indebtedness by Issuance of Shares
Marketwire - Mon Mar 31, 1:32PM CDT
AndeanGold Ltd. ("the Company" or "AndeanGold" (TSX VENTURE: AAU)(LMA: AAU) is pleased to announce that the Company has agreed to settle in full, indebtedness in the amount of $398,225.55 by the conversion thereof into 7,964,511 common shares (the "Shares" of the Company at a price of $0.05 per share in accordance with the policies of the TSX Venture Exchange.

AndeanGold Announces Closing of Second Tranche of $1.0 Million Private Placement
Marketwire - Thu Mar 27, 8:03AM CDT
AndeanGold Ltd. ("the Company" or "AndeanGold" (TSX VENTURE: AAU)(LMA: AAU) is pleased to announce that the Company has closed (the "Closing' the second tranche of its previously announced $1 million non-brokered private placement (the "Placement" (news releases of February 24, 2014 and March 25, 2014). The first tranche of the Placement closed on February 28, 2014, and involved the issuance of an aggregate of 11,796,000 Units to raise aggregate gross proceeds of $589,800 (see news release of February 28, 2014). Pursuant to the Closing, the Company issued an additional 2,011,643 Units to raise aggregate gross proceeds of $100,582.15.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 43

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 47

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 38

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 44

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 38

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 35

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched into AppLovin Corporation's Alleged Fraud

Updated Category News Views 386

Investigation into AppLovin Corporation In recent news, a substantial class action lawsuit has emerged against AppLovin Corporation (NASDAQ: APP). This national law firm, known for advocating for investors, aims to hold the company accountable for alleged securities law violations. Understanding the Class Action Lawsuit This lawsuit pertains to any individuals or entities...

Continue Reading
Safe Harbor Financial Expands Support for Cannabis Operators

Updated Category News Views 33

Safe Harbor Financial Takes Bold Step in Cannabis Financing In a remarkable move, Safe Harbor Financial has successfully arranged a secured credit facility valued at $1.07 million. This milestone supports a cannabis operator, marking a significant step in bolstering financial services within the cannabis industry. With their expertise in facilitating innovative financial...

Continue Reading
Nidec Corporation Faces Securities Investigation: Key Insights

Updated Category News Views 224

Understanding Nidec Corporation's Current Challenges Nidec Corporation is undergoing scrutiny due to serious allegations in its business practices. This Japanese manufacturer, known for its electronic components, faces potential claims of issuing misleading information to its investors. Recent developments have raised questions about its transparency and accountability in...

Continue Reading
Understanding HCI Group's Short Interest Trends and Insights

Updated Category News Views 126

An Overview of HCI Group's Short Interest HCI Group's short interest has sparked interest among traders and investors alike, showing a recent increase of 7.38% from the previous report. This shift indicates that there are currently around 404 thousand shares sold short, comprising 4.95% of the company’s total tradable shares. Observing the trading volume, it has been...

Continue Reading
Fresenius Kabi Introduces New Epinephrine Injection for Patients

Updated Category News Views 151

Fresenius Kabi Launches Epinephrine Injection, USP Fresenius Kabi, a proud branch of the Fresenius organization, has taken a significant step in enhancing its pharmaceutical portfolio in the United States by making available Epinephrine Injection, USP. This launch positions Fresenius Kabi at the forefront as it becomes the first company to offer a generic 1mg/1mL vial of...

Continue Reading